Epidemiology of psoriatic arthritis

M. Catanoso, N. Pipitone, C. Salvarani

Unità Operativa di Reumatologia, Dipartimentodi Medicina Interna, Azienda Ospedaliera ASMN, Istituto di Ricovero e Cura a Carattere Scientifico, Reggio Emilia, Italy

SUMMARY

Epidemiological studies on psoriatic arthritis have long been hampered by the absence of widely accepted classification criteria. The development of the CASPAR (ClASsification criteria for Psoriatic ARthritis) criteria has recently provided the framework for conducting epidemiological studies in psoriatic arthritis using uniform recruitment criteria. However, so far, only a minority of studies have adopted such criteria. In addition to the lack of shared classification criteria, differences in study settings, designs, and ascertainment methods have contributed to yield substantial disparities in the estimates of the incidence (from 3,02 to 23,1 cases per 100,000 people) and prevalence (from 49,1 to 420 cases per 100,000 people) of psoriatic arthritis around the globe. Overall, the available data suggests that the prevalence of psoriasis in the general population is approximately 2-3%, with about a third of patients with psoriasis having arthritis. Therefore, psoriatic arthritis may affect 0,3-1,0% of the population, a frequency not dissimilar from that of rheumatoid arthritis. Future epidemiological studies should be carried out in larger numbers of patients diagnosed using consistent criteria.

Key words: *Psoriasis, Epidemiology, Prevalence, Incidence*

Reumatismo, 2012; 64 (2): 66-70

Epidemiology aims to investigate both the distribution of rheumatic diseases and the risk factors for their development. Epidemiologic studies on psoriatic arthritis (PsA) have long been hampered by the absence of widely accepted classification criteria. As a consequence, different studies have used different sets of criteria ranging from the European Spondyloarthropathy Study Group (ESSG) (1) and Wright & Moll (2) to *ad hoc* criteria, all of which are prone to some degree to misclassifying patients. In particular, the ESSG criteria have a relatively low sensitivity and specificity (1), while the Moll and Wright criteria tend to be overinclusive (2). The recent development of the CASPAR (ClASsification criteria for Psoriatic ARthritis) criteria has provided a more robust framework for conducting epidemiological studies in PsA given the high sensitivity (0.91) and specificity (0.99) of these criteria (3). In addition, the CASPAR criteria have been validated quite extensively and have been shown to perform well, at least in established PsA (3, 4). However, only a small minority of epidemiological studies in PsA have used the CASPAR criteria.

Corresponding author:
Dr. Carlo Salvarani
Head of the Department of Rheumatology
Arcispedale Santa Maria Nuova
Viale Risorgimento, 80
42123 Reggio Emilia, Italy
E-mail: Salvarani.carlo@asmn.re.it

Other discrepancies between published studies include different study settings, designs, and ascertainment methods. These differences render difficult to compare the results from different studies, which have found widely varying estimates of incidence (from 3,02 to 23,1 cases per 100,000 people) and prevalence (from 49,1 to 420 cases per 100,000 people) (5-30). On the other hand, some differences may be genuine and reflect genetic or environmental factors. For instance, the frequency of PsA has consistently been reported to be quite low (up to 1/100,000) in Japan (7).

Most incidence studies available are retrospective in design and have used either medical records or else diagnostic or insurance codes to determine the incidence of PsA in general or Hospital populations (5-15) (Table I). Prospective studies have usually yielded higher incidence rates than retrospective studies. Data from a population-based incidence cohort suggests a rise of the incidence of PsA over the last three decades (12). However, it is debatable whether this rising incidence is genuine or simply reflects a greater awareness of physicians.

As for prevalence studies, the majority

is cross-sectional and population-based, while a minority is retrospective and based on medical records. A few studies have examined the prevalence of PsA in the population of people with psoriasis. Recent cross-sectional surveys tend to yield higher prevalence estimates than retrospective prevalence studies. (5-30) (Table II).

Many studies have reported that the onset of psoriasis typically precedes the development of arthritis. Approximately 85% of patients develop psoriasis prior to arthritis, while in 5-10% of patients both conditions develop simultaneously, and in 5-10% arthritis precedes psoriasis. There is some evidence suggesting that the severity of psoriasis is associated with an increased *risk*, although not greater *severity* of arthritis (31).

The prevalence of psoriasis in the general population is circa 2-3%, with about a third of patients with psoriasis having arthritis.

Table I - Incidence studies of PsA.

Incidence of PsA in Population					
Country	**Type of study**	**Method**	**Criteria**	**Annual Incidence Cases/10^5 (95%CI)**	**Ref.**
Finland (1996)	Retrospective	Drug reimbursement certificate	Arthritis/ spinal+ psorias/ onicop.	6.1 (4.6–7.6)	5
USA (2000)	Retrospective Popular-based	Medical record system	Arthritis + psoriasis	6.6 (5.0–8.2)	6
Japan (2001)	Retrospective	Nationwide questionnaire	Amor and ESSG	~0.05	7
Sweden (2002)	Prospective popul.-based	Primary healthcare centres	Arthritis + psoriasis+ FR-	8 (4–15)	8
Greece (2003)	Retrospective	Hospital system records	ESSG	3.02 (1.55–4.49)	9
Finland (2003)	Prospective popul.-based	Health center + local hospitals outpatients	Periph. arthritis or spinal + psoriasis	23.1 (13.2–37.5)	10
Denmark (2008)	Cross-sectional	Interview + clin. exam. + medical records	Moll & Wright CASPAR	6 (3- 11)	11
USA (2009)	Retrospective Popul.-based	Medical records (R.E.P.)	CASPAR	7.2 (6.0 - 8.4)	12
Norway (2009)	Retrospective	Diagnostic ICD-codes	Psoriasis + Arthrhitis	6.9 (3.5–11.7)	13
Czech Republiic (2010)	Popul.-based Prospective	Primary healthcare centres	Vasey and Espinoza	3.6 (1.4-7.6)	14
Argentina (2011)	Popul.-based Prospective	Medical records Diagnotic code	CASPAR	6.26 (4.2 - 8.3)	15
Incidence of PsA in Psoriasis					
Country	**Type of study**	**Method**	**Criteria**	**Incidence estimate % (95%CI)**	**Ref.**
USA (2009)	Popul.based Retrospective	diagnostic codes + medical records	CASPAR	2,7% (2,1-3,5%) 3.1% after 10 years 5.1% after 20 years	16
UK, Italy, France, Spain and Germany (2010)	Cross-sectional	Adelphy Psoriasis Program questionnaire	Psoriasis + Arthrhitis	7,4% 20.5% after 30 years	17
Canada (2011)	Prospective Longitudinal cohort	Dermatology clinics	CASPAR	1,87 % (0,71-3,03%)	18

Therefore, PsA may occur in 0.3-1.0% of the population, a frequency similar to that of rheumatoid arthritis. (see Table 1-2).

Genetic factors have been linked to both psoriasis and PsA. In particular, HLA-B13, B16 and its splits HLA-B38 and HLA-

Table II - Prevalence studies of PsA.

Prevalence of PsA in Population					
Country	**Type of study**	**Method**	**Criteria**	**Prevalence estimate Cases/105 (95%CI)**	**Ref.**
USA (2000)	Retrospective Popul-based	Medical system records	Arthritis + psoriasis	101 (81-121)	6
Japan (2001)	Retrospective	Nationwide questionnaire	Amor and ESSG	~1,0	7
Northwest Greece (2003)	Retrospective	Medical system records	ESSG	56.6 (49.9-63.2)	9
Australia (2004)	Retrospective Popul.-based	Questionnaire	Psoriasis + arth/tenos/back pain/dact/enth	500 (0.0 - 900)	19
Greece (2005)	Cross-sectional Popul.-based	Standardized questionnaire.	ESSG	170 (100-240)	20
France (2005)	Cross-sectional Popul.-based	Telephone questionnaire + physical exam	ESSG	190 (80-350)	21
Italy (2005)	Cross-sectional Popul.-based	Questionnaire + physical exam	Arthrhitis/spinal inv + Psoriasis	420 (310-610)	22
USA (2005)	Cross-sectional	Questionnaire	Patient's Self-report	250 (180-310)	23
ICELAND (2007)	Cross-sectional	Interview + clin. exam. + medical records	Psoriasis + Arthrhitis	139 (112–169)	24
CHINA (2008)	Retrospective Popul.-based	Medical system records	ESSG - Amor	~ from 10 to 100	25
Denmark (2008)	Cross-sectional	Interview + clin. exam. + medical records	Moll & Wright CASPAR	150 (130-220) 140 (110-190)	11
USA (2009)	Retrospective Popul.-based	Medical records (R.E.P.)	CASPAR	158 (132-185)	12
Norway (2009)	Retrospective	Diagnostic ICD-codes	Psoriasis + Arthrhitis	127 (106–154)	13
Czech Republiic (2010)	Popul.-based Prospective	Primary healthcare centres	Vasey and Espinoza	49.1 (39.5–60.4)	14
Argentina (2011)	Popul.-based Prospective	Medical records Diagnotic code	CASPAR	74 (57-94)	15
Prevalence of PsA in Psoriasis					
Country	**Type of study**	**Method**	**Criteria**	**Prevalence estimate % (95%CI)**	**Ref.**
ITALY (1984)	Cross-sectional	Dermatologic clinic	Moll & Wright's	34%	26
ITALY (1995)	Cross-sectional	Dermatologic clinic	Expert diagnosis M&W Amor and ESSG	36% 22% 24%	27
ITALY (2005)	Cross-sectional	Hospitalized patients	ESSG	7.7% (6.0-9.5%)	28
USA (2005)	Cross-sectional	Questionnaire	Patient's Self-report	11% (9-14%)	23
Germany (2009)	Prospective cross-sectional	dermatol. centres	Moll & Wright	20.6%(18.6-22.7%)	29
UK (2009)	Prospective cross-sectional	Questionnaire+ clin. exam.	CASPAR	13.8% (7,1-24.1%)	30
UK - Italy, France, Spain and Germany (2010)	Cross-sectional	Adelphy Psoriasis Program Questionnaire	Psoriasis + Arthrhitis	8.1%	17

B39, B17, and Cw6 have been associated with psoriasis, while HLA-B7 and B27 have been associated with PsA (32).

Some environmental factors, including HIV infection, trauma, and psychological stress appear to increase susceptibility to developing PsA. In addition, a number of clinical features including nail dystrophy, scalp lesions, and intergluteal/perianal psoriasis have been mapped to a higher likelihood of PsA (16).

Patients with PsA have been found to have increased risk factors for cardiovascular disease including hypertension, dyslipidemia and insulin resistance (33). Other studies have shown subclinical atherosclerosis and an atherogenic lipid profile (34-36). There is an increased prevalence of the metabolic syndrome in patients with psoriasis, particularly in those with moderate to severe skin disease (37).

Studies that have investigated mortality in PsA have thus far produced conflicting results, with a community-based study showing no increase in mortality (6, 12) while the analysis of a hospital-based cohort estimated a combined Standardized Mortality Ratio (SMR) for both men and women to be 1.62 (38). Recently, a single-center study suggested that mortality rates in the PsA cohort were not significantly different from those of the UK general population (39).

REFERENCES

1. Dougados M, van der Linden S, Juhlin R, et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum. 1991; 34: 1218-27.
2. Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum. 1973; 3: 55-78
3. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006; 54: 2665-73.
4. D'Angelo S, et al. Sensitivity of the classification of psoriatic arthritis criteria in early psoriatic arthritis. J Rheumatol. 2009; 36 (2): 368-70.
5. Kaipiainen-Seppanen O. Incidence of psoriatic arthritis in Finland. Br J Rheumatol. 1996; 35: 1289-91.
6. Shbeeb M, Uramoto KM, Gibson LE, O'Fallon WM, Gabriel SE. The epidemiology of psoriatic arthritis in Olmsted County,Minnesota, USA, 1982-1991. J Rheumatol. 2000; 27: 1247-50.
7. Hukuda S, Minami M, Saito T, et al. Spondyloarthropathies in Japan: nationwide questionnaire survey performed by the Japan Ankylosing Spondylitis Society. J Rheumatol. 2001; 28: 554-9.
8. Soderlin MK, Borjesson O, Kautiainen H, Skogh T, Leirisalo-Repo M. Annual incidence of inflammatory joint diseases in a population based study in southern Sweden. Ann Rheum Dis. 2002; 61: 911-5.
9. Alamanos Y, Papadopoulos NG, Voulgari PV, et al. Epidemiology of psoriatic arthritis in northwest Greece, 1982-2001. J Rheumatol. 2003; 30: 2641-4
10. Savolainen E, Kaipiainen-Seppanen O, Kroger L, Luosujarvi R. Total incidence and distribution of inflammatory joint diseases in a defined population: results from the Kuopio 2000 arthritis survey.J Rheumatol. 2003; 30: 2460-8.
11. Pedersen OB, Svendsen AJ, Ejstrup L, Skytthe A, Junker P. The occurrence of psoriatic arthritis in Denmark.Ann Rheum Dis. 2008; 67: 1422-6.
12. Wilson FC, Icen M, Crowson CS, McEvoy MT, Gabriel SE, Kremers HM. Time trends in epidemiology and characteristics of psoriatic arthritis over 3 decades: a population-based study. J Rheumatol. 2009; 36: 361-7.
13. Nossent JC, Gran JT. Epidemiological and clinical characteristics of psoriatic arthritis in northern Norway. Scand J Rheumatol. 2009; 38 (4): 251-5.
14. Hanova P, Pavelka K, Holcatova I, Pikhart H Incidence and prevalence of psoriatic arthritis, ankylosing spondylitis, and reactive arthritis in the first descriptive population-based study in the Czech Republic. Scand J Rheumatol. 2010; 39 (4): 310-7.
15. Soriano ER, Rosa J, Velozo E, Schpilberg M, et al. Incidence and prevalence of psoriatic arthritis in Buenos Aires, Argentina: a 6-year health management organization-based study. Rheumatology (Oxford). 2011; 50 (4): 729-34.
16. Wilson FC, Icen M, Crowson CS, McEvoy MT, Gabriel SE, Kremers HM. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study. Arthritis Rheum. 2009; 61: 233-9.
17. Christophers E, Barker J, Griffiths C, Daudén E, Milligan G, Molta C, et al. The risk of psoriatic arthritis remains constant following initial diagnosis of psoriasis among patients seen in European dermatology clinics. J Eur Acad Dermatol Venereol. 2010; 24: 548-54.
18. Eder L, Chandran V, Shen H, Cook RJ, Shan-

mugarajah S, Rosen CF, Gladman DD. Incidence of arthritis in a prospective cohort of psoriasis patients. Arthritis Care Res (Hoboken). 2011; 63 (4): 619-22.
19. Minaur N, Sawyers S, Parker J, Darmawan J. Rheumatic disease in an Australian Aboriginal community in North Queensland, Australia. A WHO-ILAR COPCORD survey. J Rheumatol. 2004; 31: 965.
20. Trontzas P, Andrianakos A, Miyakis S, et al. The ESORDIG Study Group. Seronegative spondyloarthropathies in Greece: a population-based study of prevalence, clinical pattern, and management. The ESORDIG study. Clin Rheumatol. 2005; 24: 583-9.
21. Saraux A, Guillemin F, Guggenbuhl P, et al. Prevalence of spondyloarthropathies in France: 2001. Ann Rheum Dis. 2005; 64: 1431-5.
22. Salaffi F, De Angelis R, Grassi W, MArche Pain Prevalence; INvestigation Group (MAPPING) study. Prevalence of musculoskeletal conditions in an Italian population sample: results of a regional community-based study. I. The MAPPING study. Clin Exp Rheumatol. 2005; 23: 819-28.
23. Gelfand JM, Gladman DD, Mease PJ, et al. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol. 2005; 53: 573-7.
24. Love TJ, Gudbjornsson B, Gudjonsson JE, Valdimarsson H. Psoriatic arthritis in Reykjavik, Iceland: prevalence, demographics, and disease course. J Rheumatol. 2007; 34: 2082-8.
25. Zeng QY, Chen R, Darmawan J, Xiao ZY, Chen SB, Wigley R, et al. Rheumatic diseases in China. Arthritis Res Ther. 2008; 10: R17.
26. Scarpa R, Oriente P, Pucino A, et al. Psoriatic arthritis in psoriatic patients. Br J Rheumatol. 1984; 23: 246-50.
27. Salvarani C,Lo Scocco G,Macchioni P, Cremonesi T, Rossi F, MantovaniW, et al. Prevalence of psoriatic arthritis in Italian psoriatic patients.J Rheumatol 1995; 22: 1499-503.
28. Gisondi P, Girolomoni G, Sampogna F, Tabolli S, Abeni D. Prevalence of psoriatic arthritis and joint complaints in a large population of Italian patients hospitalised for psoriasis. Eur J Dermatol. 2005; 15 (4): 279-83.
29. Reich K, Krüger K, Mössner R, Augustin M. Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br J Dermatol. 2009; 160: 1040-7.
30. Ibrahim G, Waxman R and Helliwell PS. The prevalence of psoriatic arthritis in people with psoriasis. 2009; 61, 10: 1373-8.
31. Gladman DD, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005; 64 (Suppl. 2): p. ii14-7.
32. Gladman DD, Farewell VT. HLA studies in psoriatic arthritis: current situation and future needs . J Rheumatol. 2003; 30 (1): 4-6.
33. Tam LS, Tomlinson B, Chu TT, Li M, Leung YY, Kwok LW, et al. Cardiovascular risk profile of patients with psoriatic arthritis compared to controls - the role of inflammation. Rheumatology. 2008; 47: 718-23.
34. Eder L, Zisman D, Barzilai M, Laor A, Rahat M, Rozenbaum M, et al. Subclinical atherosclerosis in psoriatic arthritis: a case-control study. J Rheumatol. 2008; 35: 877-82.
35. Tam LS, Shang Q, Li EK, Tomlinson B, Chu TTW, Li M, et al. Subclinical carotid atherosclerosis in patients with psoriatic arthritis. Arthritis Rheum. 2008; 59: 1322-31.
36. Jones SM, Harris CPD, Lloyd J, Stirling CA, Reckless JPD, McHugh NJ. Lipoproteins and their subfractions in psoriatic arthritis: identification of an atherogenic profile with active joint disease. Ann Rheum Dis. 2000; 59: 904-9.
37. Sommer DM, Jenisch S, Suchan, Christophers E, Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res. 2006; 298: 321-8.
38. Wong K, Gladman DD, Husted J, Long JA, Farewell VT. Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum. 1997; 40: 1868-72.
39. Buckley C, Cavill C, Taylor G, Kay H, Waldron N, Korendowych E, McHugh N. Mortality in Psoriatic Arthritis - A Single-center Study from the UK J Rheumatol. 2010; 37: 214.